The clinical importance of HGF and its receptor c-Met has been further demonstrated in recent studies, showing that the levels of c-Met in mammary cancer tissues and levels of circulating HGF in patients with mammary cancer are associated with a lower survival and development of distant metastasis [10–12]. The gene discussed is MET; the disease is breast cancer.